James Engelhart
Directeur/Membre du Conseil chez Our Lady of Mercy Academy
Postes actifs de James Engelhart
Sociétés | Poste | Début | Fin |
---|---|---|---|
Our Lady of Mercy Academy | Directeur/Membre du Conseil | - | - |
Historique de carrière de James Engelhart
Anciens postes connus de James Engelhart
Sociétés | Poste | Début | Fin |
---|---|---|---|
BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | Directeur Financier/CFO | 01/05/2016 | 15/12/2021 |
Treasurer | 01/05/2016 | 15/12/2021 | |
ALEXION PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/08/2014 | 01/05/2016 |
ENERGIZER HOLDINGS, INC. | Corporate Officer/Principal | 01/03/2006 | 01/07/2014 |
Coopers & Lybrand LLP | Corporate Officer/Principal | 01/01/1986 | 01/01/1991 |
Formation de James Engelhart
Villanova School of Business | Undergraduate Degree |
Statistiques
Internationale
Etats-Unis | 6 |
Opérationnelle
Corporate Officer/Principal | 3 |
Director of Finance/CFO | 1 |
Treasurer | 1 |
Sectorielle
Health Technology | 3 |
Consumer Non-Durables | 2 |
Commercial Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
ENERGIZER HOLDINGS, INC. | Consumer Non-Durables |
Entreprise privées | 4 |
---|---|
Biohaven Pharmaceutical Holding Co. Ltd.
Biohaven Pharmaceutical Holding Co. Ltd. Pharmaceuticals: MajorHealth Technology Biohaven Pharmaceutical Holding Co. Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders. It focuses on a pipeline of product candidates that represent mechanistic platforms, calcitonin gene-related peptide receptor antagonists, and glutamate modulators. The company was founded in September 2013 and is headquartered in New Haven, CT. | Health Technology |
Alexion Pharmaceuticals, Inc.
Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
Coopers & Lybrand LLP | Commercial Services |
Our Lady of Mercy Academy |
- Bourse
- Insiders
- James Engelhart
- Expérience